SFP
ADMA icon

Sterling Financial Planning’s ADMA Biologics ADMA Stock Holding History

Sterling Financial Planning’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed – – 103
2021
Q3 		$0 Hold
100
– – ﹤0.01% 424
2021
Q2 		$0 Hold
100
– – ﹤0.01% 398
2021
Q1 		$0 Hold
100
– – ﹤0.01% 379
2020
Q4 		$0 Buy
+100
New +$210 ﹤0.01% 355

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sterling Financial Planning's ADMA Position: Q4 2021 in Review

Sterling Financial Planning sold out of ADMA Biologics (ADMA) in Q4 2021, closing a stake of 100 shares.

Sterling Financial Planning first reported a position in ADMA in Q4 2020 and held it in 4 quarters. The position peaked at $0 in Q3 2021. 88 funds tracked by Wall St. Rank hold ADMA as of Q4 2021.

  • Sterling Financial Planning reported no remaining ADMA Biologics position as of Q4 2021 after selling out during the quarter.
  • Sterling Financial Planning sold 100 ADMA Biologics shares in Q4 2021.
  • Sterling Financial Planning first reported a position in ADMA Biologics in Q4 2020 and held it in 4 quarters.
  • Sterling Financial Planning's ADMA Biologics position peaked at $0 in Q3 2021.
  • 88 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2021.

Based on Sterling Financial Planning's 13F filing for Q4 2021, filed 2 Feb 2022.